• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome
Conclusion In this contemporary, large real-life ACS population, DAPT for more than 3 months compared with a shorter duration was associated with a lower risk of death, stroke, or re-infarction. Trial Registration Clinicaltrials.gov (NCT01623700).
Source: European Heart Journal - April 14, 2014 Category: Cardiology Authors: Varenhorst, C., Jensevik, K., Jernberg, T., Sundstrom, A., Hasvold, P., Held, C., Lagerqvist, B., James, S. Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial. Clinical trial registration information Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
Conclusions In the present trial, characterized by low event rates, we did not observe a significant difference in net clinical outcome between 6 and 12 months of clopidogrel therapy after DES implantation. However, the results of the trial must be considered in view of its premature termination and lower than expected event rates. The trial is registered with ClinicalTrials.gov, Identifier: NCT00661206.
Source: European Heart Journal - May 21, 2015 Category: Cardiology Authors: Schulz-Schupke, S., Byrne, R. A., ten Berg, J. M., Neumann, F.-J., Han, Y., Adriaenssens, T., Tolg, R., Seyfarth, M., Maeng, M., Zrenner, B., Jacobshagen, C., Mudra, H., von Hodenberg, E., Wohrle, J., Angiolillo, D. J., von Merzljak, B., Rifatov, N., Kufn Tags: Thrombosis and antithrombotic therapy Source Type: research

Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium
Conclusion</div>Ticagrelor, but not CAM, reduces expression and activity of TF and PAI-1 in LAA endocardial cells isolated from patients with AF, indicating possible local antithrombotic effects. Such pleiotropic properties of ticagrelor may contribute to a reduction in thromboembolic complications in patients with AF.</span>
Source: European Heart Journal - January 8, 2017 Category: Cardiology Source Type: research